CD44 and colonic neoplasm: Further evaluating the colon cancer stem cell (CSC) markers, we found that both CD44 and CD166 expression were reduced in the DSS-induced colon cancer samples of mice treated with the same drugs, particularly the combination of niclosamide and metformin (Figure 6G,H).